WallStSmart

Avadel Pharmaceuticals PLC (AVDL)vsViatris Inc (VTRS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Viatris Inc generates 5654% more annual revenue ($14.30B vs $248.52M). AVDL leads profitability with a -0.1% profit margin vs -24.6%. AVDL appears more attractively valued with a PEG of 0.07. VTRS earns a higher WallStSmart Score of 50/100 (C-).

AVDL

Hold

41

out of 100

Grade: D

Growth: 6.3Profit: 2.5Value: 6.7Quality: 6.0
Piotroski: 3/9Altman Z: -5.40

VTRS

Buy

50

out of 100

Grade: C-

Growth: 3.3Profit: 3.5Value: 6.7Quality: 5.5
Piotroski: 4/9Altman Z: 0.80

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AVDL2 strengths · Avg: 10.0/10
PEG RatioValuation
0.0710/10

Growing faster than its price suggests

Revenue GrowthGrowth
54.9%10/10

Revenue surging 54.9% year-over-year

VTRS2 strengths · Avg: 10.0/10
PEG RatioValuation
0.1410/10

Growing faster than its price suggests

Price/BookValuation
1.1x10/10

Reasonable price relative to book value

Areas to Watch

AVDL4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Operating MarginProfitability
2.5%3/10

Operating margin of 2.5%

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Price/BookValuation
21.4x2/10

Trading at 21.4x book value

VTRS4 concerns · Avg: 1.8/10
Return on EquityProfitability
-21.1%2/10

ROE of -21.1% — below average capital efficiency

EPS GrowthGrowth
-70.6%2/10

Earnings declined 70.6%

Altman Z-ScoreHealth
0.802/10

Distress zone — elevated risk

Profit MarginProfitability
-24.6%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : AVDL

The strongest argument for AVDL centers on PEG Ratio, Revenue Growth. Revenue growth of 54.9% demonstrates continued momentum. PEG of 0.07 suggests the stock is reasonably priced for its growth.

Bull Case : VTRS

The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.

Bear Case : AVDL

The primary concerns for AVDL are EPS Growth, Operating Margin, Piotroski F-Score.

Bear Case : VTRS

The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.

Key Dynamics to Monitor

AVDL profiles as a hypergrowth stock while VTRS is a turnaround play — different risk/reward profiles.

AVDL carries more volatility with a beta of 1.63 — expect wider price swings.

AVDL is growing revenue faster at 54.9% — sustainability is the question.

VTRS generates stronger free cash flow (551M), providing more financial flexibility.

Bottom Line

VTRS scores higher overall (50/100 vs 41/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Avadel Pharmaceuticals PLC

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Avadel Pharmaceuticals plc is a biopharmaceutical company in the United States. The company is headquartered in Dublin, Ireland.

Visit Website →

Viatris Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?